TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers

Balázs Gyorffy, Giulia Bottai, Jacqueline Lehmann-Che, György Kéri, László Orfi, Takayuki Iwamoto, Christine Desmedt, Giampaolo Bianchini, Nicholas C. Turner, Hugues de Thè, Fabrice André, Christos Sotiriou, Gabriel N. Hortobagyi, Angelo Di Leo, Lajos Pusztai, Libero Santarpia

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Breast cancers (BC) carry a complex set of gene mutations that can influence their gene expression and clinical behavior. We aimed to identify genes driven by the TP53 mutation status and assess their clinical relevance in estrogen receptor (ER)-positive and ER-negative BC, and their potential as targets for patients with TP53 mutated tumors. Separate ROC analyses of each gene expression according to TP53 mutation status were performed. The prognostic value of genes with the highest AUC were assessed in a large dataset of untreated, and neoadjuvant chemotherapy treated patients. The mitotic checkpoint gene MPS1 was the most significant gene correlated with TP53 status, and the most significant prognostic marker in all ER-positive BC datasets. MPS1 retained its prognostic value independently from the type of treatment administered. The biological functions of MPS1 were investigated in different BC cell lines. We also assessed the effects of a potent small molecule inhibitor of MPS1, SP600125, alone and in combination with chemotherapy. Consistent with the gene expression profiling and siRNA assays, the inhibition of MPS1 by SP600125 led to a reduction in cell viability and a significant increase in cell death, selectively in TP53-mutated BC cells. Furthermore, the chemical inhibition of MPS1 sensitized BC cells to conventional chemotherapy, particularly taxanes. Our results collectively demonstrate that TP53-correlated kinase MPS1, is a potential therapeutic target in BC patients with TP53 mutated tumors, and that SP600125 warrant further development in future clinical trials.

Original languageEnglish
Pages (from-to)508-519
Number of pages12
JournalMolecular Oncology
Volume8
Issue number3
DOIs
Publication statusPublished - May 2014

Keywords

  • Breast cancer subtypes
  • Chemotherapy
  • MPS1 protein kinase
  • SP600125
  • TP53 mutation status
  • Tumor relapse

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers'. Together they form a unique fingerprint.

  • Cite this

    Gyorffy, B., Bottai, G., Lehmann-Che, J., Kéri, G., Orfi, L., Iwamoto, T., Desmedt, C., Bianchini, G., Turner, N. C., de Thè, H., André, F., Sotiriou, C., Hortobagyi, G. N., Di Leo, A., Pusztai, L., & Santarpia, L. (2014). TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. Molecular Oncology, 8(3), 508-519. https://doi.org/10.1016/j.molonc.2013.12.018